We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

Mr Bourla does not say in the interview that COVID jabs are dangerous. The interview begins at the 35 seconds mark of the ...

European equities traded in the US as American depositary receipts were trending lower late Tuesday morning, declining 0.73% to 1,352.77 on the S&P Europe Select ADR Index. From continental Europe, ...

Leading vaccine makers are under investor scrutiny as Robert F. Kennedy Jr., a notable vaccine skeptic and President Donald Trump’s nominee to lead the Department of Health and Human Services (HHS), ...

DelveInsight's 'Tuberculosis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline tuberculosis ...

Pfizer and BioNTech have announced that they have submitted an Emergency Use Authorisation (EUA) to the US Food and Drug Administration (FDA) for their Omicron BA.4/BA.5-adapted bivalent COVID-19 ...

Moderna has filed complaints in the US and Germany claiming that the mRNA technology used to make Pfizer and BioNTech's Comirnaty vaccine infringes multiple patents that cover its own Spikevax shot.

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Fla., praised news that President Donald Trump will reinstate service members expelled for refusing to take the COVID-19 ...

How did we get here? February marks five years since Brexit became official. Here are some key developments since the EU-UK ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Stargate CEOs cite project’s promise of enabling cancer vaccines, though Musk joins critics in questioning partners’ ...